Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

06/24/2019 | 11:53am EDT
Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage

(Reuters) - Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion (58 billion pounds) deal.

The move sent Bristol's shares down nearly 7%, while Celgene's shares fell nearly 5%.

The psoriasis drug, which brought in revenue of around $1.61 billion last year, is currently worth around $9.3 billion, according to a net present value calculation by Credit Suisse analyst Vamil Divan, but he said Bristol-Myers could have some difficulty getting the full value.

"The key for Otezla now will be what Bristol can obtain for the asset. We believe sellers are often at a disadvantage when potential buyers know they need to divest a given asset, but there are many companies with drugs in the dermatology space that may look to bid on the asset," Divan said in a research note, adding that AbbVie Inc, Johnson & Johnson, and Eli Lilly could be interested.

Bristol announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology and cardiovascular drugs in the largest pharmaceutical industry merger ever. It had planned to close the deal in the third quarter.

However, it now expects the merger to close by the end of 2019 or the beginning of 2020.

The divestiture is subject to further review by the U.S. Federal Trade Commission (FTC) and requires Bristol to enter into a consent decree with the agency, Bristol said.

In March, the FTC had sought additional information from the companies as it focused on their psoriasis treatments as part of its review of the planned merger.

Bristol is still developing a treatment for the condition and in September reported positive results from a mid-stage trial of its plaque psoriasis drug, part of a class known as tyrosine kinase 2 (TYK-2) inhibitors.

Bristol's TYK-2 inhibitor, which is being tested for psoriasis, could be "key" for Bristol, Divan said.

The company also said it remains actively engaged in discussions with the FTC on continued review of the proposed deal.

The companies have submitted a formal application seeking European Commission clearance for the merger, Bristol said.

Separately on Monday, Bristol said its blockbuster cancer treatment Opdivo failed to meet the main goal of statistically significant improvement in overall survival in patients in a late-stage study.

(Reporting by Aakash Jagadeesh Babu in Bengaluru and additional reporting by Michael Erman in New York; Editing by Shinjini Ganguli and Shailesh Kuber)

By Aakash B


ę Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.18% 68.49 Delayed Quote.11.74%
CELGENE 0.10% 108.24 End-of-day quote.68.89%
JOHNSON & JOHNSON -0.59% 173.36 Delayed Quote.10.15%
SPACE CO.,LTD. -0.33% 909 End-of-day quote.15.21%
All news about BRISTOL-MYERS SQUIBB COMPANY
08/04BRISTOL MYERS SQUIBB : Significant Insider Sales in Shares of Bristol-Myers Squi..
MT
08/04INSIDER TRENDS : 90-Days of Insider Buying at Bristol-Myers Squibb Reduced with ..
MT
08/04INSIDER TRENDS : Insider Disposition at Bristol-Myers Squibb Scaling Back 90-Day..
MT
08/03INSIDER TRENDS : Bristol-Myers Squibb Insider Converts Option/Derivative Securit..
MT
08/03INSIDER TRENDS : Bristol-Myers Squibb Insider Disposition Scales Back 90-Days of..
MT
08/03INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of Bristol..
MT
08/03BRISTOL MYERS SQUIBB : Completes Sale of Manufacturing Facility in Couvet, Switz..
BU
08/03BRISTOL MYERS SQUIBB : Statement on Istodax« (romidepsin) Relapsed/Refractory Pe..
PU
08/03WuXi STA Pharmaceutical Co., Ltd completed the acquisition of Manufacturing F..
CI
07/30BRISTOL MYERS SQUIBB : Receives European Commission Approval for Cancer Treatmen..
MT
More news
Financials (USD)
Sales 2021 46 338 M - -
Net income 2021 6 718 M - -
Net Debt 2021 25 775 M - -
P/E ratio 2021 22,4x
Yield 2021 2,84%
Capitalization 152 B 152 B -
EV / Sales 2021 3,84x
EV / Sales 2022 3,49x
Nbr of Employees 30 250
Free-Float 76,0%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 68,49 $
Average target price 76,33 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY11.74%154 015
JOHNSON & JOHNSON10.15%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.22.77%255 703
ELI LILLY AND COMPANY55.45%232 701
NOVARTIS AG-0.20%224 638